Juno Therapeutics (JUNO) : The value of composite uptick trades was $1.76 million, whereas, the value of composite downtick trades was $2.6 million. The uptick to downtick ratio stood at 0.68 with a negative money flow of ($0.84) Million during Tuesdays trading session. The block trades money flow was negative ($0 million). The transaction of the trades on downticks amounted to $0.1 million, which confirms investors selling on the strength of price. Juno Therapeutics (JUNO) gained 1 cents at $31.82, an increase of 0.03% over the previous days close.
Also, Barclays initiates coverage on Juno Therapeutics (NASDAQ:JUNO). The shares have now been rated Equal-weight by the stock experts at the ratings house. Barclays announces the current price target of $48 per share on Juno Therapeutics . The rating by the firm was issued on July 6, 2016.
Juno Therapeutics Inc. has dropped 5.54% in the last five trading days, however, the shares have posted positive gains of 2.17% in the last 4 weeks. Juno Therapeutics Inc. has dropped 25.62% during the last 3-month period . Year-to-Date the stock performance stands at -28.29%.
Juno Therapeutics (NASDAQ:JUNO): The stock opened at $31.64 on Tuesday but the bulls could not build on the opening and the stock topped out at $32.14 for the day. The stock traded down to $31.35 during the day, due to lack of any buying support eventually closed down at $31.53 with a loss of -0.88% for the day. The stock had closed at $31.81 on the previous day. The total traded volume was 654,203 shares.
In a related news, The Securities and Exchange Commission has divulged that Klausner Richard, director of Juno Therapeutics, Inc., had unloaded 12,000 shares at an average price of $40.71 in a transaction dated on June 24, 2016. The total value of the transaction was worth $488,520.
Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Junos product candidates, JCAR015, JCAR017 and JCAR014, utilize CAR technology to target CD19, a protein expressed on the surface of various B cell leukemias and lymphomas. Junos other product candidates include JCAR018: CD22, JCAR023: L1CAM (CD171), JCAR020: MUC-16 / IL-12, ROR-1 and JTCR016: WT-1. JCAR015 is in Phase I open label clinical trial stage for patients with acute lymphoblastic leukemia (r/r ALL). JCAR017 is in Phase I/II trial for patients with pediatric r/r ALL. JCAR014 is in Phase I/II trial as a treatment for various B cell malignancies in patients. JTRC016 is in Phase I/II clinical trial for the treatment of AML, myelodysplasic syndrome and chronic myeloid leukemia.